Keywords
Lipid profile
Olanzapine
Risperidone
How to Cite
Abstract
Background: Treatment of schizophrenia requires use of antipsychotics for considerable time. Studies established that patients have risk of metabolic side effects.
Objectives: To study fasting blood glucose levels and lipid profile in schizophrenic patients and to see that same was present in study population.
Methods: This study was conducted at psychiatry outpatient department, Nobel Medical College and Teaching Hospital Kanchanbari Biratnagar from October 2018 till august 2019 after due approval from college ethics committee. A total of 50 consenting drug naive schizophrenia patients 17- 60 years of age, with no comorbidity, were divided alternatively into two groups. group 1 was treated with olanzapine, group 2 with risperidone for eight weeks. With flexible dosage for ease of the therapy and individual patient requirement. Fasting blood glucose and lipid profile was measured at day baseline, four, eight weeks.
Results: There was rise of fasting blood glucose in both groups but more in olanzapine group with no statistically significant intergroup difference (The p-value after eight weeks was 0.504). In lipid profile, mean total cholesterol levels were higher in the group 1, (p = 0.005 after eight weeks). Triglycerides, on intergroup comparison significant difference (p = 0.002) was noted. Higher values in group 1 were recorded. However, very low-density lipoprotein was elevated (p = 0.003) in group1 only.
Conclusion: olanzapine and risperidone cause non-significant rise in fasting blood sugar. Olanzapine caused statistically significant rise of total cholesterol, triglycerides, very low-density lipoprotein as compared to risperidone.
References
Hennen J, Perlis RH, Sachs G, Tohen M, Baldessarini RJ. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004 Dec;65(12):1679-87. doi: 10.4088/jcp.v65n1214.PMID:15641874. https://www.psychiatrist.com/jcp/effects/weight/weight-gain-during-treatment-bipolar-i-patients-olanzapine/.
Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65 Suppl 7:4-18; quiz 19-20. PMID: 15151456.chromeextension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.psychiatrist.com/wp-content/uploads/2021/02/18418_treatment-recommendations-psychiatrists.pdf.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005 Oct 25;112(17):2735-52. doi: 10.1161/CIRCULATIONAHA.105.169404. Epub 2005 Sep 12. Erratum in: Circulation. 2005 Oct 25;112(17):e297. Erratum in: Circulation. 2005 Oct 25;112(17):e298. PMID: 16157765. https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.105.169404
World Health Organization (WHO). (1993). The ICD-10 classification of mental and behavioral disorders. World Health Organization. (Accessed 01.01.2022), ISBN 9241544228. https://www.who.int/publications/i/item/9241544228.
Ardizzone TD, Bradley RJ, Freeman AM 3rd, Dwyer DS. Inhibition of glucose transport in PC12 cells by the atypical antipsychotic drugs risperidone and clozapine, and structural analogs of clozapine. Brain Res. 2001 Dec 27;923(1-2):82-90. doi: 10.1016/s0006-8993(01)03026-8.PMID:11743975. https://www.sciencedirect.com/science/article/abs/pii/S0006899301030268.
Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. doi: 10.1038/sj.mp.4002066. Epub 2007 Sep 11. PMID: 17848919. https://www.nature.com/articles/4002066.
Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci. 2003 Jan 1;8:d464-76.doi:10.2741/1022.PMID:12456312. https://europepmc.org/article/med/12456312.
De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, Wampers M, Scheen A, Peuskens J, van Winkel R. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008 Apr;101(1-3):295-303. doi: 10.1016/j.schres.2008.01.028.Epub 2008 Mar 4.PMID:18299188. https://www.sciencedirect.com/science/article/abs/pii/S0920996408000935.
Kim JK, Fillmore JJ, Chen Y, Yu C, Moore IK, Pypaert M, Lutz EP, Kako Y, Velez-Carrasco W, Goldberg IJ, Breslow JL, Shulman GI. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A. 2001 Jun 19;98(13):7522-7. doi: 10.1073/pnas.121164498. Epub 2001 Jun 5. PMID: 11390966; PMCID: PMC34701. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.pnas.org/doi/pdf/10.1073/pnas.121164498
McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007 Jul;164(7):1050-60. doi: 10.1176/ajp.2007.164.7.1050. PMID: 17606657. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.2007.164.7.1050.
Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003 Feb;160(2):290-6. doi: 10.1176/appi.ajp.160.2.290.PMID:12562575. https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.160.2.290.
Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004 Jan;29(1):133-45. doi: 10.1038/sj.npp.1300327. PMID: 14583740. https://www.nature.com/articles/1300327.
Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008 Nov;165(11):1420-31. doi: 10.1176/appi.ajp.2008.08050756. Epub 2008 Sep 15. Erratum in: Am J Psychiatry. 2008 Nov;165(11):1495.PMID:18794207. https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2008.08050756.
Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins AE, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005 Jan;62(1):19-28. doi: 10.1001/archpsyc.62.1.19. Erratum in: JAMA Psychiatry. 2017 Jul 1;74(7):764. Erratum in: JAMA Psychiatry. 2018 Aug 1;75(8):866. PMID: 15630069. https://jamanetwork.com/journals/jamapsychiatry/article-abstract/208155.
Zhang Y, Liu Y, Su Y, You Y, Ma Y, Yang G, Song Y, Liu X, Wang M, Zhang L, Kou C. The metabolic side effects of 12 antipsychotic drugs used for the treatment of schizophrenia on glucose: a network meta-analysis. BMC Psychiatry. 2017 Nov 21;17(1):373. doi: 10.1186/s12888-017-1539-0. PMID: 29162032; PMCID: PMC5698995. https://go.gale.com/ps/i.do?id=GALE%7CA546245920&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=1471244X&p=AONE&sw=w&userGroupName=anon%7E769873d4.
Li R, Zhang Y, Zhu W, Ding C, Dai W, Su X, Dai W, Xiao J, Xing Z, Huang X. Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis. Sci Rep. 2020 Oct 12;10(1):17028. doi: 10.1038/s41598-020-73983-4. PMID: 33046806; PMCID: PMC7552389. https://www.nature.com/articles/s41598-020-73983-4.